Aviceda enrolls first patient in phase 2 trial of AVD-104 for diabetic macular edema

Fact checked byHeather Biele

Aviceda Therapeutics has enrolled the first patient in its GLYCO phase 2 clinical trial studying AVD-104, an engineered glycan nanoparticle developed to treat diabetic macular edema.

According to a company press release, AVD-104 reduces inflammation by targeting self-pattern recognition receptors and repolarizing retinal neutrophils, macrophages and microglia to their resolution state.

eye — The GLYCO phase 2 clinical trial will enroll 30 patients with DME to determine the safety and efficacy of intravitreal AVD-104 at low and high doses. *Image: Adobe Stock*

The GLYCO study will examine the safety and efficacy of low and high doses of intravitreal AVD-104 in 30 patients with DME, with outcomes of interest including incidence and severity of ocular and systemic adverse events as well as macular thickness and vision.

“We are excited to evaluate the ability of AVD-104’s unique mechanism of action to provide DME patients with a safe treatment that may improve outcomes in eyes with DME driven by inflammatory and VEGF-mediated mechanisms,” Mohamed Genead, MD, Aviceda’s co-founder and CEO, said in the release.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Read more

Aviceda enrolls first patient in phase 2 trial of AVD-104 for diabetic macular edema

Related Content